Allergan fails to dodge pay-for-delay claim
A federal judge has ruled that plaintiffs plausibly claimed harm from Allergan’s alleged attempts to block market entry of a generic dry-eye medication.
Subscribe to Global Competition Review
Subscribe and start reading now
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10